{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rabies+vaccine", "query": { "intervention": "Rabies vaccine" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 31, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rabies+vaccine&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-19T20:04:19.412Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00000904", "title": "Safety and Effectiveness of Anti-HIV Vaccines in HIV-Negative Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "ALVAC(2)120(B,MN)GNP (vCP1452)", "type": "BIOLOGICAL" }, { "name": "gp160 MN/LAI-2", "type": "BIOLOGICAL" }, { "name": "ALVAC(1)120(B,MN)GNP (vCP1433)", "type": "BIOLOGICAL" }, { "name": "ALVAC-HIV MN120TMG (vCP205)", "type": "BIOLOGICAL" }, { "name": "ALVAC-RG Rabies Glycoprotein (vCP65)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 100, "start_date": null, "completion_date": "1999-08", "has_results": false, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-09-19T20:04:19.412Z", "location_count": 6, "location_summary": "Birmingham, Alabama • Baltimore, Maryland • St Louis, Missouri + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Rochester", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000904" }, { "nct_id": "NCT00656097", "title": "A Randomized Phase II Trial to Compare the Safety and Neutralizing Activity of CL184 in Combination With Rabies Vaccine vs. HRIG or Placebo in Combination With Rabies Vaccine in Healthy Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rabies" ], "interventions": [ { "name": "CL184", "type": "BIOLOGICAL" }, { "name": "HRIG", "type": "BIOLOGICAL" }, { "name": "Placebo matching CL184", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Crucell Holland BV", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "19 Years to 65 Years" }, "enrollment_count": 140, "start_date": "2008-03", "completion_date": "2008-07", "has_results": false, "last_update_posted_date": "2011-09-21", "last_synced_at": "2026-09-19T20:04:19.412Z", "location_count": 1, "location_summary": "Lincoln, Nebraska", "locations": [ { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT00656097" }, { "nct_id": "NCT04410900", "title": "Vaccine Responsiveness After CAR-T Cell Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B-Cell Neoplasm" ], "interventions": [ { "name": "Wistar Rabies Virus Strain PM-1503-3M Vaccine", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2020-08-03", "completion_date": "2025-08-31", "has_results": false, "last_update_posted_date": "2025-09-08", "last_synced_at": "2026-09-19T20:04:19.412Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04410900" }, { "nct_id": "NCT04062669", "title": "A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Experimental Rabies Vaccine in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Virus Diseases" ], "interventions": [ { "name": "Low dose formulation of RG SAM (CNE) vaccine (GSK3903133A)", "type": "BIOLOGICAL" }, { "name": "Medium dose formulation of RG SAM (CNE) vaccine (GSK3903133A)", "type": "BIOLOGICAL" }, { "name": "Lower dose formulation of RG SAM (CNE) vaccine (GSK3903133A)", "type": "BIOLOGICAL" }, { "name": "Lowest dose formulation of RG SAM (CNE) vaccine (GSK3903133A)", "type": "BIOLOGICAL" }, { "name": "Saline Placebo", "type": "DRUG" }, { "name": "RabAvert", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "18 Years to 40 Years" }, "enrollment_count": 160, "start_date": "2019-08-13", "completion_date": "2022-07-01", "has_results": false, "last_update_posted_date": "2024-03-01", "last_synced_at": "2026-09-19T20:04:19.412Z", "location_count": 4, "location_summary": "South Miami, Florida • Lenexa, Kansas • Baltimore, Maryland + 1 more", "locations": [ { "city": "South Miami", "state": "Florida" }, { "city": "Lenexa", "state": "Kansas" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04062669" }, { "nct_id": "NCT00023504", "title": "Antibody Production in Immune Disorders", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Primary Immune Deficiency" ], "interventions": [ { "name": "Pneumovax", "type": "BIOLOGICAL" }, { "name": "Rabavert", "type": "BIOLOGICAL" }, { "name": "Prevnar", "type": "BIOLOGICAL" }, { "name": "Tetanus diphtheria toxoid", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 21, "start_date": "2002-06-13", "completion_date": "2021-10-14", "has_results": false, "last_update_posted_date": "2021-10-15", "last_synced_at": "2026-09-19T20:04:19.412Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00023504" }, { "nct_id": "NCT03557008", "title": "Responses to Rabies Vaccine in Adults With or Without Antibiotics", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Rabies Human" ], "interventions": [ { "name": "Rabies Vaccine", "type": "BIOLOGICAL" }, { "name": "Metronidazole", "type": "DRUG" }, { "name": "Vancomycin", "type": "DRUG" }, { "name": "Neomycin Sulfate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 37, "start_date": "2018-07-05", "completion_date": "2022-06-02", "has_results": true, "last_update_posted_date": "2023-06-08", "last_synced_at": "2026-09-19T20:04:19.412Z", "location_count": 2, "location_summary": "Atlanta, Georgia • Decatur, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Decatur", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03557008" }, { "nct_id": "NCT04056117", "title": "A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Shigellosis" ], "interventions": [ { "name": "Shigella 4V", "type": "BIOLOGICAL" }, { "name": "MenACWY", "type": "BIOLOGICAL" }, { "name": "Rabies", "type": "BIOLOGICAL" }, { "name": "Diphtheria, Tetanus and Pertussis (DTaP)", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "LimmaTech Biologics AG", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "8 Months", "maximum_age": "50 Years", "sex": "ALL", "summary": "8 Months to 50 Years" }, "enrollment_count": 597, "start_date": "2019-09-02", "completion_date": "2022-11-14", "has_results": false, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-09-19T20:04:19.412Z", "location_count": 0, "location_summary": "Not listed", "locations": [], "official_url": "https://clinicaltrials.gov/study/NCT04056117" }, { "nct_id": "NCT00000946", "title": "A Study to Test the Safety of Three Experimental HIV Vaccines", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections", "HIV Seronegativity" ], "interventions": [ { "name": "HIV p24/MF59 Vaccine", "type": "BIOLOGICAL" }, { "name": "ALVAC-HIV MN120TMG (vCP205)", "type": "BIOLOGICAL" }, { "name": "ALVAC-RG Rabies Glycoprotein (vCP65)", "type": "BIOLOGICAL" }, { "name": "rgp120/HIV-1 SF-2", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 40, "start_date": null, "completion_date": "2001-03", "has_results": false, "last_update_posted_date": "2021-10-29", "last_synced_at": "2026-09-19T20:04:19.412Z", "location_count": 7, "location_summary": "Birmingham, Alabama • Baltimore, Maryland • St Louis, Missouri + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Rochester", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000946" }, { "nct_id": "NCT01784874", "title": "Comparison of Purified Vero Rabies Vaccine, Serum Free With Human Diploid Cell Vaccine in Pre-exposure Use", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rabies" ], "interventions": [ { "name": "Purified Vero Rabies Vaccine (VRVg) - Serum Free", "type": "BIOLOGICAL" }, { "name": "Imovax® Rabies: inactivated rabies vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sanofi Pasteur, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 408, "start_date": "2013-02", "completion_date": "2015-12", "has_results": false, "last_update_posted_date": "2018-02-09", "last_synced_at": "2026-09-19T20:04:19.412Z", "location_count": 6, "location_summary": "Redding, California • Sacramento, California • Omaha, Nebraska + 3 more", "locations": [ { "city": "Redding", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Austin", "state": "Texas" }, { "city": "Fort Worth", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01784874" }, { "nct_id": "NCT07399951", "title": "Washington University WU 409: Immune Responses to Rabies Vaccine.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Healthy Participants" ], "interventions": [ { "name": "Imovax", "type": "DRUG" }, { "name": "RabAvert", "type": "DRUG" }, { "name": "HyperRAB", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2023-10-19", "completion_date": "2025-10-01", "has_results": true, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-09-19T20:04:19.412Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT07399951" } ] }